Skip to content

Study · Animal study (in vivo) · cattle, chicken and monkey · 1984

20 results

On the in vitro and in vivo activity of a new synthetic hexapeptide that acts on the pituitary to specifically release growth hormone.

Bowers CY, Momany FA, Reynolds GA, Hong A

Endocrinology1 May 1984Cited by 338 (Europe PMC)

PMID6714155 (opens in a new tab)DOI10.1210/endo-114-5-1537 (opens in a new tab)PepBankPUB-06714155
Publisher pagePubMedAsk about this study
Jump to 20 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study20

18 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In limited animal studies, GHRP elicited GH release without concomitant insulin release.

    In plain wordsIn limited animal studies, GHRP released growth hormone without releasing insulin.

    Peptide
    GHRP-6
    Outcome
    No significant changeInsulin release selectivity
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In limited animal studies, GHRP elicited GH release without concomitant glucagon release.

    In plain wordsIn limited animal studies, GHRP released growth hormone without releasing glucagon.

    Peptide
    GHRP-6
    Outcome
    No significant changeGlucagon release selectivity
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In rats, GHRP was active after intravenous, subcutaneous, or intraperitoneal administration.

    In plain wordsIn rats, GHRP was active after administration into a vein, under the skin, or into the abdominal cavity.

    Peptide
    GHRP-6
    Outcome
    IncreaseActivity by administration route
    Study

    ratn: not reported in source

    rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · iv, sc, or ipAs given in this study (rat).

    Source sentences

    Summary
    It was active when administered iv, sc, or ip to rats.
  4. 04AnimalAnimal study (in vivo)Efficacy outcome

    In rats, GHRP stimulated GH release.

    In plain wordsIn rats, GHRP stimulated growth hormone release.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH release in rats
    Study

    ratn: not reported in source

    rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was active in rats, monkeys, lambs, calves, and under special experimental conditions chicks, indicating its lack of species dependency.
    1 context sentence
    Summary · context
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  5. 05AnimalAnimal study (in vivo)Efficacy outcome

    In monkeys, GHRP stimulated GH release.

    In plain wordsIn monkeys, GHRP stimulated growth hormone release.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH release in monkeys
    Study

    monkeyn: not reported in source

    monkeys
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was active in rats, monkeys, lambs, calves, and under special experimental conditions chicks, indicating its lack of species dependency.
    1 context sentence
    Summary · context
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  6. 06AnimalAnimal study (in vivo)Efficacy outcome

    In lambs, GHRP stimulated GH release.

    In plain wordsIn lambs, GHRP stimulated growth hormone release.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH release in lambs
    Study

    sheepn: not reported in source

    lambs
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was active in rats, monkeys, lambs, calves, and under special experimental conditions chicks, indicating its lack of species dependency.
    1 context sentence
    Summary · context
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  7. 07AnimalAnimal study (in vivo)Efficacy outcome

    In calves, GHRP stimulated GH release.

    In plain wordsIn calves, GHRP stimulated growth hormone release.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH release in calves
    Study

    cattlen: not reported in source

    calves
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was active in rats, monkeys, lambs, calves, and under special experimental conditions chicks, indicating its lack of species dependency.
    1 context sentence
    Summary · context
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  8. 08AnimalAnimal study (in vivo)Efficacy outcome

    In chicks under special experimental conditions, GHRP stimulated GH release.

    In plain wordsIn chicks under special experimental conditions, GHRP stimulated growth hormone release.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH release in chicks
    Study

    chickenn: not reported in source

    chicks under special experimental conditions
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    It was active in rats, monkeys, lambs, calves, and under special experimental conditions chicks, indicating its lack of species dependency.
    1 context sentence
    Summary · context
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  9. 09AnimalAnimal study (in vivo)Efficacy outcome

    In rats, GH rose within 2 min after GHRP injection, peaked at 10-20 min, and usually normalized by 2 h.

    In plain wordsIn rats, growth hormone rose rapidly after intravenous GHRP and usually returned to normal by 2 h.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response time course after intravenous injection
    Study

    ratn: not reported in source

    rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · intravenousAs given in this study (rat).

    Source sentences

    Summary
    After iv injection, GH levels rose within 2 min, peaked at +10-20 min, and by 2 h usually had returned to normal.
    1 context sentence
    Summary · context
    It was active when administered iv, sc, or ip to rats.
  10. 10AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the GH response to GHRP lasted longer than the response to GHRF-44.

    In plain wordsIn rats, GHRP stimulated growth hormone release for longer than GHRF-44.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response duration
    Study

    ratn: not reported in source

    rats
    Comparator
    GHRF-44
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    The GH response of [His1,Lys6]GHRP was longer in duration than either of these larger peptides.
    1 context sentence
    Summary · context
    It was not possible to directly compare the potencies of [His1,Lys6]GHRP, and the GH-releasing factors GHRF-44 and GHRF-40 after a single sc injection in rats because the time course of the GH response of these peptides was different.
  11. 11AnimalAnimal study (in vivo)Efficacy outcome

    In rats, the GH response to GHRP lasted longer than the response to GHRF-40.

    In plain wordsIn rats, GHRP stimulated growth hormone release for longer than GHRF-40.

    Peptide
    GHRP-6
    Outcome
    IncreaseGH response duration
    Study

    ratn: not reported in source

    rats
    Comparator
    GHRF-40
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneousAs given in this study (rat).

    Source sentences

    Summary
    The GH response of [His1,Lys6]GHRP was longer in duration than either of these larger peptides.
    1 context sentence
    Summary · context
    It was not possible to directly compare the potencies of [His1,Lys6]GHRP, and the GH-releasing factors GHRF-44 and GHRF-40 after a single sc injection in rats because the time course of the GH response of these peptides was different.
  12. 12AnimalAnimal study (in vivo)Efficacy outcome

    In immature rats, GHRP once or twice daily for 9 or 25 days increased body weight gain above control.

    In plain wordsIn immature rats, daily GHRP injections increased body weight gain compared with control.

    Peptide
    GHRP-6
    Outcome
    IncreaseBody weight gain
    Study

    ratn: not reported in source

    immature rats
    Comparator
    control
    Outcome group
    Body weight · Metabolic and weight
    Studied dose
    Dose not stated · subcutaneous · 9 or 25 daysAs given in this study (rat).

    Source sentences

    Summary
    When this small peptide was administered sc once or twice daily to immature rats for 9 or 25 days, the BW gain increased above the control.
  13. 13AnimalAnimal study (in vivo)Efficacy outcome

    In immature rats, the pituitary remained fully responsive to GHRP at the end of the weight-gain studies.

    In plain wordsIn immature rats, the pituitary remained fully responsive to GHRP after the weight-gain studies.

    Peptide
    GHRP-6
    Outcome
    No significant changePituitary responsiveness after weight-gain studies
    Study

    ratn: not reported in source

    immature rats
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated · subcutaneous · 9 or 25 daysAs given in this study (rat).

    Source sentences

    Summary
    At the end of the weight gain studies the pituitary remained fully responsive to the peptide.
    1 context sentence
    Summary · context
    When this small peptide was administered sc once or twice daily to immature rats for 9 or 25 days, the BW gain increased above the control.
  14. 14AnimalOther designEfficacy outcome

    In preclinical models, GHRP elicited GH release without concomitant LH release.

    In plain wordsIn preclinical models, GHRP released growth hormone without releasing LH.

    Peptide
    GHRP-6
    Outcome
    No significant changeLH release selectivity
    Study

    n: not reported in source

    in vitro and in vivo models
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  15. 15AnimalOther designEfficacy outcome

    In preclinical models, GHRP elicited GH release without concomitant FSH release.

    In plain wordsIn preclinical models, GHRP released growth hormone without releasing FSH.

    Peptide
    GHRP-6
    Outcome
    No significant changeFSH release selectivity
    Study

    n: not reported in source

    in vitro and in vivo models
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  16. 16AnimalOther designEfficacy outcome

    In preclinical models, GHRP elicited GH release without concomitant TSH release.

    In plain wordsIn preclinical models, GHRP released growth hormone without releasing TSH.

    Peptide
    GHRP-6
    Outcome
    No significant changeTSH release selectivity
    Study

    n: not reported in source

    in vitro and in vivo models
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  17. 17AnimalOther designEfficacy outcome

    In preclinical models, GHRP elicited GH release without concomitant PRL release.

    In plain wordsIn preclinical models, GHRP released growth hormone without releasing prolactin.

    Peptide
    GHRP-6
    Outcome
    No significant changePRL release selectivity
    Study

    n: not reported in source

    in vitro and in vivo models
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    Dose not stated

    Source sentences

    Summary
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.
  18. 18LabEx vivo tissueEfficacy outcome

    In pituitary incubates, GHRP was active over the reported minimum-to-maximum dosage range.

    In plain wordsIn lab tests, GHRP stimulated growth hormone release in pituitary incubates at the reported concentrations.

    Peptide
    GHRP-6
    Outcome
    IncreaseActive concentration range
    Study

    n: not reported in source

    pituitary incubate assay
    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones
    Studied dose
    1-10 ng/mlAs given in this study.

    Measurements

    Active dosage range
    1 to 10 ng/ml
    pituitary incubate assay

    Source sentences

    Summary
    In vitro the minimum and maximum active dosages ranged from 1-10 ng/ml in the pituitary incubate assay.
    1 context sentence
    Summary · context
    His-DTrp-Ala-Trp-DPhe-LysNH2, [His1,Lys6] GHRP, is a new synthetic hexapeptide which specifically elicits a dosage-related release of GH in vitro and in vivo without a concomitant release of LH, FSH, TSH, or PRL and, in limited in vivo studies, insulin or glucagon.

Studies that did not test the peptide alone2

In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking GHRP-6.

  1. 19AnimalNot a test of GHRP-6 aloneAnimal study (in vivo)Mechanism

    In animals, SRIF-14 and SRIF-28 inhibited the GHRP response, with SRIF-28 7.5 times more active.

    In plain wordsIn animals, both somatostatins inhibited the GHRP response, with SRIF-28 more active than SRIF-14.

    Peptide
    GHRP-6
    Outcome
    DecreaseSomatostatin inhibition of GH response in vivo
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Measurements

    Relative SRIF-28 activity
    7.5 times
    versus SRIF-14 in vivo

    Source sentences

    Summary
    Both SRIF-14 and SRIF-28 inhibited the GH response of the hexapeptide; however, SRIF-28 was about four times more active than SRIF-14 in vitro and 7.5 times more active in vivo.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

  2. 20LabNot a test of GHRP-6 aloneIn vitro (cells)Mechanism

    In vitro, SRIF-14 and SRIF-28 inhibited the GHRP response, with SRIF-28 about four times more active.

    In plain wordsIn lab tests, both somatostatins inhibited the GHRP response, with SRIF-28 more active than SRIF-14.

    Peptide
    GHRP-6
    Outcome
    DecreaseSomatostatin inhibition of GH response in vitro
    Study

    n: not reported in source

    Outcome group
    Growth hormone and IGF-1 · Endocrine and hormones

    Source sentences

    Summary
    Both SRIF-14 and SRIF-28 inhibited the GH response of the hexapeptide; however, SRIF-28 was about four times more active than SRIF-14 in vitro and 7.5 times more active in vivo.

    In this study, GHRP-6 was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking GHRP-6.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    21 Oct 2026, 15:59 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:13 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.